World hemoglobin A1c monitoring market is forecast to surpass $272 million by 2012. The market is primarily driven by an ever increasing diabetic population. Other growth drivers include greater glucose control and product innovations that help improve compliance or convenience.
San Jose, CA (PRWEB) October 28, 2008 -- World Health Organization forecasts global diabetic population to increase by 2025 to reach a record 380 million. Globally, an estimated 246 million people are affected by diabetes mellitus, of which less than half have been identified. Of those identified, approximately 10%-20% are insulin dependent. The seriousness of affliction and the need for effective therapy to manage diabetes has led to the emergence of a significant market for monitoring the treatment efficiency of the disease. Other factors such as greater glucose control, product innovations that help improve compliance or convenience comprise other growth drivers in this market.
Diabetes patients (type I) who regularly monitor their HbA1c (hemoglobin A1C) levels attain tight glucose control, thus considerably reducing their vulnerability to a cardiovascular disease. High blood sugar level for a longer period of time could result to increase in risk of heart disease or stroke. An HBA1C level more that 4.6 indicate the person is at increased risk for heart attack. The ADA (American Diabetes Association), recommends an HbA1c test every 3 to 6 months for monitoring the levels of blood sugar in insulin-administered patients, patients with high blood glucose levels and patients with a change of therapy.
World Hemoglobin (Hb) A1c monitoring market is projected to expand to US$272 million by 2012, as stated by Global Industry Analysts, I
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |